Health Condition 1: H341- Central retinal artery occlusion
Conditions
Interventions
Intervention1: Administration of intravitreal Anti - VEGF: The patient will be administered intravitreal bevacizumab under sterile precautions. 0.05ml of 1.25mg bevacizumab is dose that will be admini
Sponsors
Dr Shivraj Tagare
Eligibility
Inclusion criteria
Inclusion criteria: Treatment naïve patients with RVO macular edema in any one eye, presenting to the outpatient department of the Retina Clinic at Aravind Eye Hospital, Pondicherry. Age above 18 years old.
Exclusion criteria
Exclusion criteria: Cases of RVO induced macular edema previously treated with intravitreal anti-VEGF bevacizumab injections, steroid injections or photocoagulation and macular edema due to any other cause. Patient opting for antiVEGF other than bevacizumab will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in CRT/CMT recorded on an OCT. Timepoint: 1. Change in CRT/CMT recorded on an OCT after 1 month of intravitreal anti-VEGF injection | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in SRF at the fovea on an OCT. 2. Betterment in visual acuity. 3. Correlation of the above with systemic factors and duration of disease. Timepoint: 1. Change in SRF at the fovea on an OCT after 1 month of giving intravitreal anti VEGF injection. 2. Correlation of the above with systemic factors and duration of disease. | — |
Countries
India
Contacts
Public ContactDr Shivraj Tagare
Aravind Eye Hospital
Outcome results
None listed